咳喘胶囊联合舒利迭治疗咳嗽变异型哮喘19例  

Nineteen Cases of Cough-Variant Asthma Treated with Kechuan Capsule in Combination with Seretide

作　　者：常力[1] 

机构地区：[1]天津中医药大学第一附属医院,天津300193

出　　处：《河南中医》2016年第3期496-498,共3页Henan Traditional Chinese Medicine

摘　　要：目的:观察咳喘胶囊联合舒利迭治疗咳嗽变异型哮喘的临床疗效。方法:将40例咳嗽变异型哮喘风痰阻肺证患者随机分为治疗组和对照组,每组20例。在研究过程中,治疗组因随诊失访脱落1例;对照组因随诊失访脱落2例。实际完成观察和参与统计分析的病例治疗组为19例,对照组为18例。对照组予舒利迭气雾剂吸入治疗,治疗组在对照组治疗的基础上给予咳喘胶囊口服治疗。结果:治疗组愈显率78.9%,对照组愈显率61.1%,治疗组优于对照组(P<0.05);治疗组治疗后证候积分、复发率均优于对照组(P<0.05);两组治疗后FEVI和PEFR均有明显改善(P<0.05)。结论:咳喘胶囊联合舒利迭治疗咳嗽变异型哮喘风痰阻肺证疗效显著。Objective： To observe the clinical curative effect of Kechuan Capsule（ KCC） in combination with Seretide on cough-variant asthma. Methods： Forty patients with cough-variant asthma due to syndrome of wind-phlegm obstructing the lung were randomly divided into the treatment group and the control group,with 20 cases in each group. During the research process,one case in the treatment group,two cases in the control group were shed off due to failure in follow-up,so only 19 cases and 18 cases in the treatment group and in the control group actually took part in observation and statistical analysis of the research. The ones in the control group were given Seretide aerosol for inhalation treatment,while the ones in the treatment group were added KCC based on the treatment of the control group. Results： The remarkable healing rate of the treatment group was 78. 9%,while that of the control group was 61. 1%; And the treatment group was better than the control group（ P 〈 0. 05）. After the treatment,the syndrome score,and the recurrence rate of the treatment group were all better than those of the control group（ P 〈 0. 05）. After the treatment,FEVI and PEFR of the two groups were obviously improved（ P 〈 0. 05）. Conclusion： KCC in combination with Seretide has remarkable clinical curative effect on cough-variant asthma.

关 键 词：咳嗽变异性哮喘 风痰阻肺证 咳喘胶囊 舒利迭 

分 类 号：R256.12[医药卫生—中医内科学]